Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Oct 19;2005(4):CD003497.
doi: 10.1002/14651858.CD003497.pub2.

Combined vitamin B6-magnesium treatment in autism spectrum disorder

C Nye  1 , A Brice
Affiliations

Combined vitamin B6-magnesium treatment in autism spectrum disorder

C Nye et al. Cochrane Database Syst Rev. .

Abstract

Background: The use of mega-vitamin intervention began in the 1950s with the treatment of schizophrenic patients. Pyroxidine (vitamin B6) was first used with children diagnosed with "autism syndrome" when speech and language improvement was observed in some children as a result of large doses of B6. A number of studies attempted to assess the effects of vitamin B6-Magnesium (Mg) was found to reduce undesirable side effects from B6) on characteristics such as verbal communication, non-verbal communication, interpersonal skills, and physiological function, in individuals with autism.

Objectives: To determine the efficacy of vitamin B6 and magnesium (B6-Mg) for treating social, communication, and behavioural responses of children and adults with autism.

Search strategy: We searched the Cochrane Controlled Trials Register (Cochrane Library, Issue 2, 2002), MEDLINE (1966 to January 2002), EMBASE (1980 to January 2002), PsycINFO (1887 to January 2002), Dissertation Abstracts International (1861 to January 2002). The search engine FirstSearch was also used (January 2002). All searches were updated in April 2005. Reference lists for all the obtained studies and other review articles were examined for additional studies.

Selection criteria: All studies in which the participants had been diagnosed with autistic spectrum disorder were randomly allocated prior to intervention and in which outcomes were compared to either a placebo or non-treated group were included.

Data collection and analysis: Two reviewers independently evaluated and extracted data from all potential studies identified for inclusion.

Main results: This update includes a new trial (Kuriyama 2002) to bring the total of included studies to three (total n=33). One study, which used a cross-over design (Tolbert 1993) provided insufficient data to conduct an analysis. Another crossover study (Findling 1997) yielded no significant differences between treatment and placebo group performances following the B6 intervention on measures of social interaction, communication, compulsivity, impulsivity, or hyperactivity. The latest study (Kuriyama 2002) was motivated by evidence from epilepsy research and was focussed on a subgroup of children with pervasive developmental disorders (PDDs) who exhibited clinical features similar to those with pyroxidine-dependent epilepsy. This small study (n=8) only measured IQ and 'Social Quotient' and found a statistically significant benefit for IQ (5.2, 95% CI = [0.2 to 10.3]) when in the treated group, by using change scores.

Authors' conclusions: Due to the small number of studies, the methodological quality of studies, and small sample sizes, no recommendation can be advanced regarding the use of B6-Mg as a treatment for autism.

PubMed Disclaimer

Conflict of interest statement

None known.

Figures

1.1
1.1. Analysis
Comparison 1 Intelligence quotient (IQ), Outcome 1 B6 versus placebo.
2.1
2.1. Analysis
Comparison 2 Verbal intelligence quotient, Outcome 1 B6 versus placebo.
3.1
3.1. Analysis
Comparison 3 Perfomance IQ, Outcome 1 B6 versus placebo.
4.1
4.1. Analysis
Comparison 4 Social quotient (SQ), Outcome 1 B6 versus placebo.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Findling 1997 {published data only}
    1. Findling RL, Maxwel K, Scotese‐Wojtila L, Husang J, Yamashita T, Wiznitzer M. High‐dose pyridoxine and magnesium administration in children with autistic disorder: An absence of salutary effects in a double‐blind, placebo‐controlled study. Journal of Autism and Developmental Disabilities 1997;27(4):467‐478. - PubMed
Kuriyama 2002 {published and unpublished data}
    1. Kuriyama S, Kamiyama M, Watanabe M, Tamahashi S, Muraguchi I, Watanabe T, et al. Pyridoxine treatment in a subgroup of children with pervasive developmental disorders. Developmental Medicine & Child Neurology 2002;44:283‐286. - PubMed
Tolbert 1993 {published data only}
    1. Tolbert L, Haigler T, Waits MM, Dennis T. Brief report: Lack of response in an autistic population to a low dose clinical trial of pyridoxine plus magnesium. Journal of Autism and Developmental Disabilities 1993;23(1):193‐199. [MEDLINE: ] - PubMed

References to studies excluded from this review

Barthelemy 1980 {published data only}
    1. Barthelemy C, Garreau B, Leddet I, Sauvage D, Domenech J, Muh JP, Lelord G. Biological and clinical effects of oral magnesium and associated magnesium‐vitamin B6 administration on certain disorders observed in infantile autism (author's transl). Therapie 1980;35(5):627‐632. [MEDLINE: ] - PubMed
Barthelemy 1981 {published data only}
    1. Barthelemey C, Garbeau B. Leddet I, Ernouf D, Muh JP, Lelord G. Behavioral and biological effects of oral magnesium, vitamin B6, and combined magnesium‐B6 administration in autistic children. Magnesium Bulletin 1981;2:150‐153.
Barthelemy 1983 {published data only}
    1. Barthelemy C, Garreau B, Leddet I, Sauvage D, Muh JP, Lelord G, Callaway E. Value of behavior scales and urinary homovanillic acid determinations in monitoring the combined treatment with vitamim B6 and magnesium of children displaying autistic behavior [Interet des echelles de comportement et des dosages de l'acide homovanilique urinaire pour le controle des effets d'un traitement associant vitamine B6 et magnesium chez des enfants ayant un comportement autistique]. Neuropsychiatrie de l Enfance et de l'Adolescence 1983;31(5‐6):289‐201. - PubMed
Barthelemy 1985 {published data only}
    1. Barthelemy C, Martineau J, Bruneau N, Garreau B, Barthelelemy, Muh JP, Lelord, G. Marqueurs cliniques (items d'echelles de comportement), electrophysiologiques (potentials evoques conditionnes) et biochimiques (acide homovanillique urinaire) dans l'autisme de l'enfant [Clinical (behavioral scale items), electrophysiological (evoked potentials) and biochemical (urinary HVA) markers in autistic children.]. L'Encephale 1985;11:101‐106. - PubMed
Bönisch 1968 {published data only}
    1. Bonish E. Experiences with pyrithioxin in brain‐damaged children with autistic syndrome [Erfahrungen mit Pyrithioxin bei hirngeschadigten Kindern mit autistischem Syndrom]. Praxis der Kinderpsychologie und Kinderpsychiatrie. 1968;17(8):308‐310. - PubMed
Jonas 1984 {published data only}
    1. Jonas C, Etienne T, Barthelemy C, Jouve J, Mariotte N. Clinical and biochemical value of Magnesium + vitamin B6 combination in the treatment of residual autism in adults [Interet clinique et biochimique de l'association vitamine B6 + magnesium dans le traitement de l'autisme residuel a l'age adulte]. Therapie 1984;39(6):661‐669. [MEDLINE: ] - PubMed
Lelord 1978 {published data only}
    1. Lelord G, Callaway E, Muh JP, Arlot JC, Sauvage, D, Garreau B, Domenech J. L'acide homovanilique urinaire et ses modifications par ingestion de vitamine B6: Exploration fonctionnelle dans l'autisme de l'enfant? Rev. Neurol (Paris) 1978;134(12):797‐801.Lelord G, Muh JP, Barthelemy C, Martineau J, Garreau J. Effects of pyridoxine and magnesium on autistic symptoms‐initial observations [Modifications in urinary homovanillic acid after ingestion of vitamin B6; functional study in autistic children (author's transl)]. Rev. Neurol (Paris) 1978;134(12):797‐801. [MEDLINE: ] - PubMed
Lelord 1981 {published data only}
    1. Lelord G, Muh JP, Barthelemy C, Martineau J, Garreau J. Effects of pyridoxine and magnesium on autistic symptoms‐initial observations. Journal of Autism and Developmental Disabilities 1981;11(2):219‐230. - PubMed
Lelord 1982 {published data only}
    1. Lelord G, Callaway E, Muh JP. Clinical and biological effects of high doses of vitamin B6 and Magnesium on autistic children. Acta Vitaminologica et Enzymologica 1982;4(1‐2):27‐44. - PubMed
Martineau 1981 {published data only}
    1. Martineau J, Garreau B, Barthelemy C. Effects of vitamin B6 on averaged evoked potentials in infantile autism. Biological Psychiatry 1981;16(7):627‐641. - PubMed
Martineau 1982 {published data only}
    1. Martineau J, Garreau B, Barthelemy C, Callaway E, Lelord G. Comparative effects of oral B6 Mg and Mg administration on evoked potentials conditioning in autistic children. In: Rothenberger editor(s). Event‐related potentials in children. New York: Elsevier Biomedical Press, 1982:411‐416.
Martineau 1985 {published data only}
    1. Martineau J, Barthelemy C, Garreau B, Lelord G. Vitamin B6, magnesium, and combined B6‐Mg: therapeutic effects in childhood autism. Biological Psychiatry 1985;20(5):467‐478. - PubMed
Martineau 1988 {published data only}
    1. Martineau J, Barthelemy C, Cheliakine C, Lelord G. Brief Report: An open middle‐term study of combined vitamin B6‐Magnesium in a subgroup of autistic children selected on their sensitivity to this treatment. Journal of Autism and Developmental Disorders 1988;18(3):435‐447. [MEDLINE: ] - PubMed
Martineau 1989 {published data only}
    1. Martineau J, Barthelemy C, Roux S, Garreau B, Lelord G. Electrophysiological effects of fenfluramine or combined vitamin B6 and magnesium on children with autistic behaviour. Developmental Medicine & Child Neurology 1989;31(6):721‐727. [MEDLINE: ] - PubMed
Menage 1992 {published data only}
    1. Menage P, Thibault G, Barthelemy C, Lelord G, Bardos P. CD4+ CD45RA+ T lymphocyte deficiency in autistic children: effect of a pyridoxine‐magnesium treatment. Brain Dysfunction 1992;5(5‐6):326‐333.
Rimland 1978 {published data only}
    1. Rimland B, Callaway E, Dreyfus P. The effect of high doses of Vitamin B6 on autistic children: a double‐blind crossover study. American Journal of Psychiatry 1978;135(4):472‐475. [MEDLINE: ] - PubMed

Additional references

Alderson 2004
    1. Alderson P, Green S, Higgins JPT. Cochrane Reviewers' Handbook 4.2.2 (updated December 2003). In: The Cochrane Library, Issue 1, 2004. Chichester UK: John Wiley & Sons Ltd, 2004.
Ananth 1973
    1. Ananth JV, Ban TA, Lehmann HE. Potentiation of therapeutic effects of nicotinic acid by pyridoxine in chronic schizophrenics. Canadian Psychiatric Association Journal 1973;18(5):377‐83. - PubMed
APA 1994
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐IV). Fourth. Washington, DC: American Psychiatric Association, 1994.
Bucci 1973
    1. Bucci L. Pyridoxine and schizophrenia. British Journal of Psychiatry 1973;122(567):240. - PubMed
Campbell 1985
    1. Campbell M, Palij M. Behavioral and cognitive measures used in psychopharamocologic studies of infantile autism. Psychopharamacology Bulletin 1985;21:1047‐1053. - PubMed
DiLalla 1994
    1. DiLalla D, Rogers SJ. Domains of the Childhood Autism Rating Scale; Relevance for diagnosis and treatment. Journal of Autism and Developmental Disorders 1994;24:115‐128. - PubMed
Egger 1997
    1. Egger M, Davey Smith G, Schneider, M, & Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;315(7109):629‐34. - PMC - PubMed
Fombonne 1999
    1. Fombonne E. The epidemiology of autism: a review. Psychological Medicine 1999;29:769‐786. - PubMed
Fombonne 2003
    1. Fombonne E. The prevalence of autism. JAMA 2003;289:87‐89. - PubMed
Freeman 1986
    1. Freeman BJ, Ritvo ER, Yokota A, Ritvo A. A scale for rating symptoms of patients with the syndrome of autism in real life settings. Journal of the American Academy of Child Psychiatry 1986;25(1):130‐136. - PubMed
Goyette 1978
    1. Goyette CH, Conners, CK, Ulrich RF. Normative data on revised Conners parent and teacher rating scales. Journal of Abnormal Child Psychology 1978;6:221‐236. - PubMed
Greenberg 1970
    1. Greenberg GH. An evaluation of niacinamide in the treatment of childhood schizophrenia. American Journal of Psychiatry 1970;127(1):89‐96. [MEDLINE: ] - PubMed
Insel 1983
    1. Insel TR, Murphy, DL, Cohen, RM, Alterman I, Kilts C, Linnoila M (. Obsessive‐compulsive disorder: A double‐blind trial of clomipramine and clorgyline. Archives of General Psychiatry 1983;40:605‐612. - PubMed
NIMH 1985
    1. National Institutes of Mental Health. Clinical Global Impression Scale. Psychopharamacology Bulletin 1985;21:839‐843.
Overall 1988
    1. Overall JE, Campbell M. Behavioral assessment of psychopathology in children: Infantile autism. Journal of Clinical Psychology 1988;44:708‐716. - PubMed
Pfeiffer 1996
    1. Pfeiffer SL, Norton J, Nelson L, Schott S. Efficacy of vitamin B6 and magnesium in the treatment of autism: A methodology review and summary of outcomes. Journal of Autism and Developmental Disorders 1996;25(5):481‐493. - PubMed
Rimland 1964
    1. Rimland B. Infantile autism: The syndrome and its implications for neural theory of behavior. New York: Appleton Century Crofts, 1964.
Rimland 1973
    1. Rimland B. High‐doseage levels of certain vitamins in the treatment of children with mental disorders. In: Hawkins D, Pauling L editor(s). Orthomolecular psychiatry: treatment of schizophrenia. San Francisco, CA: W. H. Freeman, 1973.
Schaumberg 1983
    1. Schaumberg H, Kaplan J, Windebank A, Vick N, Rasmus S, Pleasure D, Brown MJ. Sensory neuropathy from pyridoxine abuse. New England Journal of Medicine 1983;309:445‐8. - PubMed
Schopler 1980
    1. Schopler E, Reichler RJ, DeVellis RF, Daly K. Toward objective classification of childhood autism: Childhood autism rating scale (CARS). Journal of Autism and Developmental Disabilities 1980;1:91‐103. - PubMed

Publication types